enGene (NASDAQ:ENGN) Posts Earnings Results, Misses Estimates By $0.06 EPS

Key Points

• enGene reported quarterly earnings of ($0.57) per share, missing analysts' expectations by ($0.06).
• The company's stock traded down $0.23 to reach $6.06 during trading hours on Thursday, with a market cap of $309.67 million.
• HC Wainwright has maintained a "buy" rating for enGene, setting a target price of $25.00 on the shares, with an average rating of "Buy" among analysts.

enGene (NASDAQ:ENGN - Get Free Report) issued its earnings results on Thursday. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06), Zacks reports.

enGene Stock Up 1.7%

NASDAQ ENGN traded up $0.10 during trading on Tuesday, hitting $6.07. 152,190 shares of the company traded hands, compared to its average volume of 217,187. enGene has a 12 month low of $2.65 and a 12 month high of $11.00. The business has a fifty day simple moving average of $4.21 and a 200 day simple moving average of $4.12. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $310.18 million, a P/E ratio of -3.19 and a beta of -0.39.

Analysts Set New Price Targets

Several analysts recently issued reports on ENGN shares. Morgan Stanley cut their price objective on enGene from $19.00 to $18.00 and set an "overweight" rating for the company in a report on Friday. HC Wainwright reiterated a "buy" rating and set a $25.00 price objective on shares of enGene in a report on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $21.00.

Hedge Funds Weigh In On enGene

An institutional investor recently bought a new position in enGene stock. Paloma Partners Management Co bought a new stake in shares of enGene Holdings Inc. (NASDAQ:ENGN - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,319 shares of the company's stock, valued at approximately $38,000. Institutional investors and hedge funds own 64.16% of the company's stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.